Share this article on:

The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART

Belmonte, Lilianaa; Olmos, Martinc; Fanin, Anac; Parodi, Ceciliaa; Baré, Patriciaa; Concetti, Hugod; Pérez, Héctorb; de Bracco, Maria Marta Ea; Cahn, Pedrob

doi: 10.1097/QAD.0b013e3282efb74b
Research Letters

The presence of HIV-1 RNA in distal duodenal mucosa was evaluated in 44 HIV-1-positive patients. HIV-1 RNA was detected in gut tissue in antiretroviral-naive patients with high plasma viral loads, as well as in patients on HAART with plasma viral loads below the limit of detection and in patients on HAART with virological failure. The intestinal mucosa seems to serve as a reservoir poorly influenced by levels of plasma viral load or HAART.

aInstituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina

bInfectious Diseases Unit, Argentina

cGastroenterology Unit, Argentina

dPathology Unit, Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Received 25 September, 2006

Accepted 14 November, 2006

With the use of HAART, it is now possible to reduce plasma HIV-1 RNA to undetectable levels and increase CD4 T-cell counts in peripheral blood in the majority of adherent patients [1,2]. T lymphocytes in peripheral blood represent only 2–5% of the total of lymphocytes in the body, whereas the majority of lymphocytes are located in lymphoid tissues. Gut-associated lymphoid tissue (GALT) represents the largest lymphoid organ. It is extremely permissive to HIV-1 infection and supportive of HIV-1 replication, providing a persistent viral reservoir [3–5]. Several studies have demonstrated that replication-competent virus persists in blood cells and lymphoid tissue after at least 2 years of HAART, despite the complete suppression of HIV-1 RNA in blood [6–8]. The presence of HIV-1 in intestinal mucosa has been demonstrated, but there are relatively few reports of the effects of HAART in these tissues [9–11].

In this study we examined the presence of HIV-1 RNA in paraffin-embedded distal duodenal mucosa biopsies from 44 HIV-positive patients by in-situ hybridization. Twenty-five out of 44 patients had been on HAART for more than 4 years. The characteristics and clinical data of the participants in the study were: 30 men, 14 women; average CD4 T-cell count 265 ± 222 cells/μl (mean ± SD); mean age 38.2 ± 7 years; mode of transmission men who have sex with men, 18 cases; heterosexual transmission, 19; intravenous drug users, six; transfusion, one. As controls, distal duodenal mucosa biopsies from 10 HIV-1-seronegative individuals were also analysed.

The duodenal mucosa biopsies were obtained for diagnostic purpose and the remaining tissue was embedded in paraffin and used for the in-situ hybridization analysis later. This protocol was reviewed and approved by the Ethics Committee of the Academia Nacional de Medicina and Juan A. Fernandez Hospital.

The HIV-RNA concentration in plasma was determined using the Amplicor HIV monitor quantitative assay (Roche Diagnostic Systems, Branchburg, New Jersey, USA). CD4 lymphocyte counts were determined by flow cytometry (Becton-Dickinson, San Jose, California, USA).

Twenty-five out of the 44 HIV-1-positive patients had HIV-1 RNA detectable in plasma (plasma viral load > 100 000 copies/ml). The remaining 19 patients had undetectable HIV-1 RNA (< 50 copies/ml).

In-situ hybridization using biotin-labeled probes and tyramide signal amplification (DakoCytomation, Gen Point; Dako Denmark A/S, Denmark) was performed to allow the qualitative detection of HIV-1 RNA in duodenal mucosa sections from patients with chronic HIV infection. Two probes were used: Gag/5′ genome 5′GGA TGT ACT CTA TCC CAT TCT GCA GCT TCC TCA 3′; Rev probe 5′TCC TGC CAT AGG AGA TGC/CAG TCG CCG CCC CTC 3′. The signal was developed by adding the chromogenic indicator dye diaminobencidine, which is oxidized by the peroxidase enzymes. The specificity of the in-situ hybridization was demonstrated by the lack of signals in the duodenal biopsies from HIV-1-seronegative patients or when the probe was omitted from the hybridization mixture. The slides were counterstained with haematoxilin. Visualization of in-situ hybridization signals was carried out using an Olympus microscope equipped with 20×, 40×, 60× and 100× objectives (Fig. 1a).

Fig. 1

Fig. 1

Positive HIV-1 hybridization signals were observed in the duodenal biopsies from 20 of the 44 HIV-1 patients (45.5%). Ten of the 20 HIV-1-positive duodenal biopsies corresponded to patients who had plasma viral loads below 50 copies/ml and 10 to patients who had plasma viral loads greater than 100 000 copies/ml (P = 0.4 ns, chi-square test).

Analysing the relationship of therapy to the detection of virus, HIV-1 RNA was detected in duodenal biopsies from 10 out of 19 HIV-positive patients off HAART. HIV-1 RNA was also detected in duodenal specimens collected from 10 out of 25 HIV-positive patients receiving HAART, 19 of them with confirmed viral suppression below 50 copies/ml (Fig. 1b).

Our results show that HIV RNA can be detected in patients with successful HAART, confirming that residual HIV reservoirs remain in spite of successful treatment. HAART inhibits viral replication but does not eradicate the virus from cellular reservoirs [6–8]. Studies examining peripheral blood alone provide a limited view of AIDS pathogenesis. In the present study, considering the effects of HAART on intestinal HIV-1-RNA detection, approximately half of the untreated patients with high plasma viral loads gave positive duodenal results. The results were similar in patients on successful HAART having undetectable plasma viral loads. It thus seems that the detection of HIV-1 RNA in the duodenum was not influenced by treatment. No differences in the mean percentage of HIV-1-positive biopsies were found between patients on and off HAART.

Moreover, in six patients who failed HAART no HIV-1 RNA was observed in duodenal biopsies, confirming the lack of correlation between the plasma viral load and intestinal HIV detection.

In our study the plasma viral load did not predict the presence of HIV-1 RNA in the duodenum. These data suggest that the intestinal mucosa can be a reservoir that is not influenced by levels of plasma viral load or antiretroviral therapy. Ongoing HIV replication in the intestine may be a source that repopulates the body with virus after therapy is withdrawn.

Our results confirm that it is important to study the sites of low replication in order to improve our understanding of the pathogenesis of HIV disease.

Sponsorship: This work was supported by grants from the Argentinian National Ministry of Health, Carrillo-Oñativia research fellowship.

Back to Top | Article Outline


1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112–116.
2. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70–79.
3. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708–11717.
4. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761–770.
5. Kotler DP, Reka S, Borcich A, Cronin WJ. Detection, localization, and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol 1991; 139:823–830.
6. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CS, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291–1295.
7. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaison RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295–1300.
8. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193–13197.
9. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, et al. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 2003; 17:53–63.
10. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236–8247.
11. Lampinen TM, Critchlow CW, Kuypers JM, Hurt CS, Nelson PJ, Hawes SE, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000; 14:F69–F75.
© 2007 Lippincott Williams & Wilkins, Inc.